SCY-770 Updated Oct 25
Watch for the Phase 2 proof-of-concept study initiation in Q4 2026 (imminent) and, more importantly, the early efficacy readout on total kidney volume expected in the second half of 2027. SCY-770 must demonstrate a meaningful reduction in kidney growth versus placebo to justify the valuation implied by analyst targets (~$36 mean). Until then, the stock is driven by SCY-247 antifungal progress and the $214M BARDA contract, SCY-770 remains a high-risk/high-reward pipeline component.
- First-in-class mechanism targeting root cause of ADPKD with no disease-modifying oral options beyond Tolvaptan (Jynarque), which has tolerability issues
- FDA Orphan Drug Designation provides 7-year market exclusivity, regulatory fee waivers, and potential accelerated approval via total kidney volume surrogate endpoint
- Phase 1 showed clean safety at doses higher than previously tested, 273 subjects dosed across 8 trials with prior PXL770 studies, supporting the dose range for Phase 2
- SCY-770 has ZERO efficacy data in ADPKD patients, the prior PXL770 Phase 2a in NASH (a different disease) missed its primary endpoint on liver fat reduction
- Phase 2 is still a proof-of-concept study; the early efficacy readout (H2 2027) is binary and could fail to show meaningful total kidney volume reduction
- Tolvaptan (Jynarque, Otsuka) is already approved and established with a large treated population; competitive entrant needs to demonstrate superiority or better tolerability